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Abstract
Background: Felid herpesvirus 1 (FHV-1) causes upper respiratory tract diseases in cats worldwide, including nasal
and ocular discharge, conjunctivitis and oral ulceration. The nature and severity of disease can vary between clinical
cases. Genetic determinants of virulence are likely to contribute to differences in the in vivo phenotype of FHV-1
isolates, but to date there have been limited studies investigating FHV-1 genetic diversity. This study used next
generation sequencing to compare the genomes of contemporary Australian clinical isolates of FHV-1, vaccine
isolates and historical clinical isolates, including isolates that predated the introduction of live attenuated vaccines
into Australia. Analysis of the genome sequences aimed to assess the level of genetic diversity, identify potential
genetic markers that could influence the in vivo phenotype of the isolates and examine the sequences for evidence
of recombination.
Results: The full genome sequences of 26 isolates of FHV-1 were determined, including two vaccine isolates and
24 clinical isolates that were collected over a period of approximately 40 years. Analysis of the genome sequences
revealed a remarkably low level of diversity (0.0–0.01 %) between the isolates. No potential genetic determinants of
virulence were identified, but unique single nucleotide polymorphisms (SNPs) in the UL28 and UL44 genes were
detected in the vaccine isolates that were not present in the clinical isolates. No evidence of FHV-1 recombination
was detected using multiple methods of recombination detection, even though many of the isolates originated
from cats housed in a shelter environment where high infective pressures were likely to exist. Evidence of
displacement of dominant FHV-1 isolates with other (genetically distinct) FHV-1 isolates over time was observed
amongst the isolates obtained from the shelter-housed animals.
Conclusions: The results show that FHV-1 genomes are highly conserved. The lack of recombination detected in
the FHV-1 genomes suggests that the risk of attenuated vaccines recombining to generate virulent field viruses is
lower than has been suggested for some other herpesviruses. The SNPs detected only in the vaccine isolates offer
the potential to develop PCR-based methods of differentiating vaccine and clinical isolates of FHV-1 in order to
facilitate future epidemiological studies.
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Background
Felid herpesvirus 1 (FHV-1), an alphaherpesvirus, causes
upper respiratory tract disease in cats that is charac-
terised by pyrexia, severe nasal and ocular discharge,
conjunctivitis and oral ulceration. It is a common cause
of necrotising upper respiratory tract infections (URI) in
cats housed in shelters, with more than 50 % of cats
shedding virus only one week after admission [1]. The
virus typically replicates in epithelial cells of the con-
junctiva and the upper respiratory tract and infects local
neurons, establishing latency in the trigeminal, pterygo-
palatine and cranial cervical ganglia [2]. Although virus
replication is generally limited to the upper respiratory
tract and conjunctiva, viraemia has been detected during
the acute phase of infection [3, 4] and a recent report
has described a case of non-suppurative meningo-
encephalitis in cats, suggesting that FHV-1 has potential
to cause more invasive disease [5]. Vaccination has been
used to help control disease caused by FHV-1 since the
mid-1970s. Both attenuated and inactivated vaccines are
in use currently, and while they can reduce the severity
of disease, they do not prevent infection [6–9].
Early studies demonstrated that isolates of FHV-1 were
antigenically indistinguishable using conventional sero-
logical techniques. Additionally, a high level of genomic
homogeneity was identified using restriction endonucle-
ase cleavage analyses [10, 11]. A subsequent restriction
endonuclease cleavage analysis study of 78 Japanese iso-
lates detected three FHV-1 genotypes, although these
genotypes still appeared to be very similar [12]. Since
these early studies there has been only limited investiga-
tion of the extent of variation between vaccine and wild
type strains of FHV-1.
This study aimed to use next generation sequencing to
compare the genomes of contemporary Australian clin-
ical isolates of FHV-1 to those of historical clinical iso-
lates, including isolates that predate the introduction of
live attenuated vaccines into Australia. Analysis of the
genome sequences aimed to assess the level of genetic
diversity, identify potential genetic markers that could
influence the in vivo phenotype of the isolates and
examine the sequences for evidence of recombination.
Results
Genome sequence analysis of 26 FHV-1 isolates
The full genome sequences of a panel of 26 FHV-1 iso-
lates were assembled and analysed. This included 24
Australian clinical field isolates spanning nearly 40 years,
as well as isolates from two currently available vaccines.
The genome sequence of the prototype C-27 FHV-1
strain (GenBank:NC_013590), a historical isolate from
North America, was also included in the analysis [13].
The genomes of the Feligen vaccine isolate of FHV-1 as-
sembled by two different methods (de novo assembly
and map to reference assembly) were identical, with the
exception of the regions containing short sequence re-
peats. This provided a high level of confidence in gen-
ome assembly by mapping to a reference sequence and
this method was used for all other FHV-1 isolates in this
study. Genome sequence data have been deposited into
GenBank under the accession numbers as listed in
Table 1 [GenBank:KR296657 and GenBank:KR381779 -
KR381803]. The size of the FHV-1 full genomes ranged
from 133.5 kbp (isolate 3227–05) to 135.1 kbp (isolate
3225–05). Genome length variation occurred primarily
as a result of differences in the large sequence repeat re-
gions (IRS/TRS) and in the unique short region as a re-
sult of tandem repeat iterations.
Despite the long time span over which the isolates
were obtained, alignment of the FHV-1 genomes (Fig. 1a)
revealed that diversity between them only ranged from
0.0 to 0.01 %. While the limited geographical range of
many of the Australian isolates could have influenced
this, three of the genomes analysed in this study were
from isolates of North American origin. The most
genetically diverse isolates (135/68 from 3225/05 and
3230/05), differed genome-wide by only 83 single nu-
cleotide polymorphisms (SNPs), while some isolates
shared 100 % nucleotide identity (excluding large regions
of tandem repeat reiterations). The identical viruses in-
cluded 356/75 with 571/79, while the eleven 2004/2005
field isolates differed by 0 to 4 SNPs, and the three 2006
isolates differed by 1 or 2 SNPs. The two vaccines were
identical (excluding large reiterative repeat regions) and
so are both likely to have been derived from the widely
used F2 strain. The C-27 strain, a field strain isolated
contemporaneously with the F2 vaccine strain from the
USA, varied from the F2-derived vaccine strains by only
5 SNPs genome-wide (excluding large reiterative repeat
regions) [14, 15]. The non-synonymous nucleotide dif-
ferences (SNPs and insertions/deletions, or indels), as in-
dicated by predicted amino acid residue differences
between isolates, are provided in Table 2.
Phylogenetic and recombination analyses of FHV-1
isolates
Phylogenetic analyses revealed that FHV-1 isolates fell
into two main groups (Fig. 1b). Whilst some isolates
with known geographical or temporal associations did
cluster together (for example all 2004 and 2005 isolates),
overall there was no clear relationship between viral gen-
ome sequences, the geographical location where the
virus was isolated, the year of virus isolation or whether
they predated the date of introduction of the attenuated
FHV-1 vaccine into Australia in 1977. No clear associ-
ation was detected between the genome sequence and
the presence or nature of disease in the cat from which
the virus was isolated.
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Discussion
The genome sequences of Australian isolates that
predated the introduction of the FHV-1 vaccine into
Australia (in 1977) had a high sequence identity with
isolates obtained since then, and also with isolates ori-
ginating from the USA. Overall, our data demonstrated
that FHV-1 genomes are highly conserved, more so than
any of the other herpesviruses analysed to date, with a
similar study of equine herpesvirus 1 (EHV-1) isolates
finding variation of between 5 and 173 SNPs between
EHV-1 isolates [16]. Previous studies have suggested
greater differences between FHV-1 isolates, including re-
arrangements in the UL44 (gC) gene [17], restriction
endonuclease cleavage site differences in the UL17 gene
[18], and differences in MluI cleavage patterns across
the genome [11]. However, all the isolates examined
in our study had conserved gene arrangements, with
only one SNP detected in UL44 (a non-synonymous
substitution), and the predicted restriction endonucle-
ase cleavage patterns generated from the sequence
data varied mainly as a result of variations in short
tandem repeat iterations.
This study included analyses of fourteen FHV-1 iso-
lates from cats housed in an animal shelter between
2004 and 2006. The cluster of viruses from this shelter
in 2004 and 2005 is of particular interest because of the
apparent transience of a dominant virus in a shelter en-
vironment. The SNP profile of the viruses from 2004 to
2005 was distinct from those of all the other isolates se-
quenced, but this pattern was not detected in the 2006
isolates from the same shelter. The close phylogenetic
relationship between the viruses isolated in 2004/2005,
and between those collected in 2006, suggests endemic
circulation in each of these periods, with clear evidence
Table 1 FHV-1 isolates sequenced in this study
Virus ID Year Origina Disease Site Vacc Otherb GenBank Reference
85/68 1968 Shelter A URTI Nasal swab N 6 mo female, febrile KR381787 [31]
117/68 1968 Shelter A URTI Nasal swab N 7 wo KR381780 [31]
124/68b 1968 Shelter A URTI Nasal swab N 8 yo, female KR381788 This study
135/68a 1968 Shelter A URTI Nasal swab N n/a KR381786 This study
221/71 1971 Private URTI, conjunct Eye swab N 3.5 wo female Persian KR381781 This study
356/75b 1975 Blackburn URTI n/a N Siamese KR381784 This study
384/75 1975 Mornington Pneumonia Lung N 5 wo female Burmese KR381782 This study
448/77 1977 Private n/a Pharynx swab N n/a KR381783 This study
571/79 1979 Albert Park Conjunct Eye swab N Male KR381785 This study
729/83 1983 Balwyn Conjunct n/a Y 3 mo KR381779 This study
3224/04 2004 Shelter B URTI, oral ulcer Nasal swab Y 4 yo male DSH KR381792 This study
3225/05 2005 Shelter B Absent Eye swab Y 10 wo male DLH KR381801 This study
3226/05 2005 Shelter B URTI Oral swab Y 9 wo male DSH KR381793 This study
3227/05 2005 Shelter B Absent Nasal swab Y 15 wo male DSH KR381802 This study
3228/05 2005 Shelter B Oral ulcer Nasal swab Y 10 wo female DSH KR381794 This study
3229/05 2005 Shelter B URTI Eye swab n/a 16 wo male DLH KR381795 This study
3230/05 2005 Shelter B URTI Nasal swab Y 1 yo male DSH KR381796 This study
3231/05 2005 Shelter B Oral ulcer, conjunct Oral swab Y 8 wo male, DLH KR381797 This study
3232/05 2005 Shelter B Oral ulcer Eye swab Y 9 wo female DSH KR381798 This study
3233/05 2005 Shelter B URTI, diarrhea Oral swab Y 12 wo female DSH KR381799 This study
3234/05 2005 Shelter B URTI Eye swab Y 8 wo female DSH KR381800 This study
3235/06 2006 Shelter B URTI, conjunct Oral swab Y 5 wo male DSH KR381789 This study
3236/06 2006 Shelter B URTI Eye swab Y 4 yo male Siamese KR381791 This study
3238/06 2006 Shelter B URTI Oral swab Y 2 yo male DSH KR381790 This study
3239/14 2013 USA - Vaccine - FeligenRCP Virbac KR296657 -
3240/14 2013 USA - Vaccine - Companion Intervet KR381803 -
aAll isolates sequenced, excluding vaccine isolates, were from Victoria, Australia
bDSH domestic short hair, DLH domestic long hair, yo year old, mo month old, wo week old, URTI upper respiratory tract infection, Conjunct conjunctivitis, Y/N yes/
no, n/a data not available
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of displacement of the 2004/2005 viruses by those de-
tected in 2006. This displacement may have occurred as
a result of increased transmissibility of the newer vi-
ruses, or management changes, such as seasonal crowd-
ing [19], depopulation and repopulation of the shelter, or
sampling bias (only samples free of feline calicivirus
were selected for use in this study).
In vitro studies have reported a high rate of recombin-
ation in FHV-1 [20]. However, no evidence of recombin-
ation was detected between the 27 FHV-1 isolates,
irrespective of genomic region analysed or the program
used (P > 0.05). It is possible that recombination events
may not have been detected because of the low levels of
diversity among the viruses in our study. It is also pos-
sible that previous in vitro studies may have overesti-
mated the likelihood of FHV-1 recombination because
of the use of high multiplicities of infection and simul-
taneous infection, as both these factors have been shown
in previous studies to increase the rate of recombination
in vitro in other herpesviruses [21]. Recombination
would be predicted in circumstances where the oppor-
tunity for co-infection is high and where the recombin-
ant progeny have a survival advantage over the parent
viruses and dominant field strains. While infective pres-
sure in a shelter environment would be expected to
allow concurrent infections with different FHV-1 iso-
lates, there may be insufficient selective pressure on
recombinants for them to emerge and persist in vivo in
a natural (shelter) environment, particularly as the low
levels of diversity among FHV-1 viruses may result in in-
sufficient selective distinction for specific viruses to
emerge in a population.
Fig. 1 Nucleotide sequence alignment and phylogenetic tree of the complete genomes of 27 FHV-1 isolates, excluding the terminal repeat region.
a Alignment of the complete genome sequences of FHV-1 isolates performed using MAFFT. The Feligen vaccine F2 isolate was used as the reference
sequence. Vertical black lines indicate SNPs relative to the reference and dashes indicate sequence gaps. b Phylogenetic tree generated from the
complete genome alignment, using the Jukes Cantor model and the neighbor-joining method. One thousand bootstrap replicates were used to
assess the significance of the tree topology. The bar indicates nucleotide substitutions per site. The origin of isolates is indicated to the right of the
isolate name
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Conclusions
Attenuated herpesvirus vaccines are used not only
against FHV-1 in cats, but also against Marek’s disease
virus and infectious laryngotracheitis virus (ILTV) in
poultry, bovine herpesvirus 1 in cattle, pseudorabies
virus in swine, and EHV-1 and equine herpes virus 4
(EHV-4) in horses. Previous studies of ILTV in poultry
have demonstrated that attenuated vaccine strains can
participate in natural recombination events that lead to
the generation of more virulent progeny [22]. The risk
of recombination involving other attenuated veterinary
herpesvirus vaccines has not been evaluated comprehen-
sively, but the risk appears to higher in some viruses
(such as EHV-4) and lower in others (such as EHV-1)
[16]. The results from this study suggest that the risk for
FHV-1 vaccine recombination may also be low. Al-
though the FHV-1 genome sequencing data from this
study confirms the findings of earlier studies that FHV-
1 s are relatively homogeneous [11] this study did detect
SNPs unique to F2-derived vaccine strains, in genes
UL28 and UL44. A search of all FHV-1 sequences avail-
able on GenBank identified only nine sequences cover-
ing these regions of the FHV-1 genomes, all relating to
the UL44 gene. None of the sequences contained the
vaccine-specific SNP, however the sequences were
mostly of unknown origin apart from two; a BAC of the
C-27 strain [GenBank:GM036023] and strain C7301
[GenBank:D86616]. There is the potential to use the F2-
derived vaccine unique SNPs to differentiate vaccine
FHV-1 isolates from other circulating FHV-1 s, and thus
facilitate future epidemiological studies in FHV-1, espe-
cially to investigate the epidemiology of attenuated
FHV-1 vaccines. Sequencing of more geographically
Table 2 Amino acid residue changes resulting from
non-synonymous nucleotide polymorphisms, including insertions/
deletions, compared to the reference isolate (F2 strain) of FHV-1




UL5 T7I 124/68, 3235/06, 3236/06, 3238/06
UL13 S25P 85/68, 117/68, 124/68, 135/68, 221/71, 356/75,






UL27 P872L 3235/06, 3236/06, 3238/06
UL28 Q427P All
UL29 S1089P Field









P2838S 85/68, 117/68, 124/68, 135/68, 221/71, 356/75,














ICP0 S412F 356/75, 571/79
Unique short region
US7 M165T Field
P186S 124/68, 3235/06, 3236/06, 3238/06
Table 2 Amino acid residue changes resulting from
non-synonymous nucleotide polymorphisms, including insertions/
deletions, compared to the reference isolate (F2 strain) of FHV-1
(Continued)
Repeat region
ICP4 T156N 124/68, 3235/06, 3236/06, 3238/06
A419V 85/68, 117/68, 124/68, 135/68, 221/71, 3235/06,
3236/06, 3238/06
H875Q 385/75
V983A 356/75, 571/79, 3224/04, 3225/05, 3226/05,
3227/05, 3228/05, 3229/05, 3230/05, 3231/05,
3232/05, 3233/05, 3234/05
E1034K 3235/06, 3236/06, 3238/06
E1054G 2004/2005
US1 L261- 85/68
aAA amino acid change
bRelative to the vaccine isolates (F2 FHV-1 strains from the Feligen/Companion
vaccines). All = Variant found in all non-vaccine isolates, Field = Variant found
only in all Australian isolates sequenced in this study, 2004/2005 = Variant
unique to 2004/2005 field isolates
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diverse isolates will help confirm whether these SNPs
are suitable markers for such studies.
Methods
Viruses and genome sequencing
Ten historical and fourteen recent Australian FHV-1 iso-
lates, as well as two live attenuated vaccines currently
available in Australia (Table 1) were selected from our
laboratory archive. Historical isolates were obtained
from clinical samples submitted to our laboratory as a
component of past diagnostic services. Recent samples
were collected from shelter-housed cats in 2004 to
2006 with approval from the Faculty of Veterinary
Science, Animal Ethics Committee at The University
of Melbourne (reference number 0004055.1) and with
the consent from the shelter owners. Viruses were
propagated in cultures of Crandell Rees feline kidney
(CRFK) cells [23] for six passages, during which three
plaque purifications were performed. CRFK cells are
derived from a normal, female, 12 weeks old cat and
are commercially available (ATCC CCL-94). Isolates
selected for sequencing dating from 2004 to 2006
were all from animals that were negative for feline
calicivirus, as determined by RT-PCR [24]. Viral nu-
cleocapsid genomic DNA was purified and sequenced
as described previously [16]. Libraries were prepared
using 50 ng of viral genomic DNA with the Illumina
Nextera DNA library preparation kits according to
manufacturer’s instructions, and loaded onto an Illumina
MiSeq. Sequencing was carried out using a 300 cycle V2
SBS kit (Illumina) in paired-end format. Reads were
trimmed to an error probability limit of 0.5 % and mapped
against the prototype FHV-1 sequence, strain C-27
[GenBank:NC_013590], using medium-low sensitivity op-
tions in the bioinformatics package Geneious V6.1.7 [25].
For comparison, a de novo assembly of the genome of the
F2 strain of FHV-1 from the Feligen vaccine (Virbac) was
also performed using the medium-low sensitivity settings
in Geneious. The details of the sequencing metrics are
provided in Additional file 1: Table S1.
Phylogenetic and recombination analyses
Alignments of the complete genome sequences of the
FHV-1 isolates, excluding the terminal repeat regions
(TRS), were prepared using the Multiple Alignment with
Fast Fourier Transformation (MAFFT) version 7 plugin
in Geneious [26]. The F2 vaccine strain of FHV-1 was
used as the reference sequence. The historical C-27
strain of FHV-1 was also included throughout the ana-
lyses. Phylogenetic analyses were performed on the
complete genome sequences, excluding the TRS and
large sequence gaps, using the neighbor-joining method
in Geneious with the Jukes Cantor model of nucleotide
substitution [27]. One thousand bootstrap replicates
were used to assess the significance of the phylogenetic
tree topology.
To detect evidence of historical recombination
events between the isolates, two programs were used,
SplitsTree4 [28] and RDP4 [29], as previously de-
scribed [16]. Short tandem repeat regions were identi-
fied in the aligned genomes prior to analysis using
the Phobos plugin in Geneious V6.1.7. Default set-
tings and score constraints for satellites with a max-
imum repeat unit length of 50 nucleotides were used.
The identified repeat regions were removed from all
viruses in the alignment as the methods used in this
study do not allow the length of these regions to be
accurately determined, and differences in the length
of these regions could give rise to false positive re-
combination events being detected. The resultant whole
genome alignments, as well as the separate UL, US and
IRS genomic region alignments, were analysed for evi-
dence of recombination. Splits network trees were gener-
ated with an uncorrected P characters transformation
model, ignoring gapped sites. Other models were tested
but yielded no significant topological differences. Statis-
tical analyses of the recombination networks were per-
formed using the Phi test as implemented in SplitsTree4
[30]. In RDP4 six different methods were used to assess
the sequences for recombination breakpoints, MaxChi,
Bootscan, SiScan, Chimaera, GENECONV and RDP, with
default RDP4 settings used throughout.
Additional file
Additional file 1: Table S1. FHV-1 sequencing metrics, viral genome
sequence details. (DOCX 17 kb)
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